The trading price of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) floating lower at last check on Monday, September 20, closing at $1.06, -3.84% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.06 and $1.1175. In examining the 52-week price action we see that the stock hit a 52-week high of $2.34 and a 52-week low of $0.38. Over the past month, the stock has gained 7.84% in value.
Adamis Pharmaceuticals Corporation, whose market valuation is $163.80 million at the time of this writing, is expected to release its quarterly earnings report Nov 08, 2021 – Nov 12, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.06 per share this quarter, however they have predicted annual earnings per share of -$0.23 for 2021 and -$0.2 for 2022. It means analysts are expecting annual earnings per share growth of 64.10% this year and 13.00% next year.
Analysts have forecast the company to bring in revenue of $3.47 million for the current quarter, with the likely lows of $1.23 million and highs of $5.7 million. The average estimate suggests sales will likely down by -25.60% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $13.68 million. The company’s revenue is forecast to drop by -17.20% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Adamis Pharmaceuticals Corporation No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest ADMP has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned ADMP a recommendation rating is 1. Out of them, 1 rate it a Hold, while 0 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Adamis Pharmaceuticals Corporation (ADMP) as Underweight, while 0 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that ADMP’s price is currently -3.13% off the SMA20 and 0.91% off the SMA50. The RSI metric on the 14-day chart is currently showing 47.65, and weekly volatility stands at 5.66%. When measured over the past 30 days, the indicator reaches 6.46%. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)’s beta value is currently sitting at 1.32, while the Average True Range indicator is currently displaying 0.06.
To see how Adamis Pharmaceuticals Corporation stock has been performing today in comparison to its peers in the industry, here are the numbers: ADMP stock’s performance was -3.84% at last check in today’s session, and 39.24% in the past year, while SIGA Technologies Inc. (SIGA) has been trading -1.18% in recent session and positioned -4.65% lower than it was a year ago. Another comparable company Johnson & Johnson (JNJ) saw its stock trading -0.09% lower in today’s session but was up 11.95% in a year. Furthermore, Pfizer Inc. (PFE) showed an increase of 1.18% today while its price kept inclining at 25.78% over the past year. Adamis Pharmaceuticals Corporation has a P/E ratio of 0, compared to SIGA Technologies Inc.’s 12.07 and Johnson & Johnson’s 24.77. Also during today’s trading, the S&P 500 Index has plunged -1.63%, while the Dow Jones Industrial also saw a negative session, down -1.55% today.
An evaluation of the daily trading volume of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) indicates that the 3-month average is 3.83 million. However, this figure has increased over the past 10 days to an average of 1.54 million.
Currently, records show that 148.89 million of the company’s shares remain outstanding. The insiders hold 1.06% of outstanding shares, whereas institutions hold 11.10%. The stats also highlight that short interest as of Jul 29, 2021, stood at 10.95 million shares, resulting in a short ratio of 2.8 at that time. From this, we can conclude that short interest is 7.36% of the company’s total outstanding shares. It is noteworthy that short shares in July were up slightly from the previous month’s figure, which was 9.23 million. However, since the stock’s price has seen 126.76% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.